Literature DB >> 19100371

Immunotherapy in acute leukemia.

Wing Leung1.   

Abstract

Recent advances in immunotherapy of cancer may represent a successful example in translational research, in which progress in knowledge and technology in immunology has led to new strategies of immunotherapy, and even past failures in many clinical trials have led to a better understanding of basic cancer immunobiology. This article reviews the latest concepts in antitumor immunology and its application in the treatment of cancer, with particular focus on acute leukemia.

Entities:  

Mesh：

Year:  2009        PMID： 19100371      PMCID： PMC2839547          DOI： 10.1053/j.seminhematol.2008.09.004

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  201 in total

Review 1.  Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Int J Cancer       Date:  2002-01-20       Impact factor: 7.396

2.  Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

Authors:  Mirjam H M Heemskerk; Renate S Hagedoorn; Menno A W G van der Hoorn; Lars T van der Veken; Manja Hoogeboom; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2006-09-12       Impact factor: 22.113

3.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Authors:  Claudia M Kowolik; Max S Topp; Sergio Gonzalez; Timothy Pfeiffer; Simon Olivares; Nancy Gonzalez; David D Smith; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

4.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors:  John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

5.  Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells.

Authors:  Tanja A Gruber; Dianne C Skelton; Donald B Kohn
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

6.  Leukemia-associated antigenic isoforms induce a specific immune response in children with T-ALL.

Authors:  Alexander Michael Dohnal; Andrea Inthal; Thomas Felzmann; Sebastian Glatt; Wolfgang Sommergruber; Georg Mann; Helmut Gadner; E Renate Panzer-Grümayer
Journal:  Int J Cancer       Date:  2006-12-15       Impact factor: 7.396

7.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.

Authors:  J P Medema; J de Jong; L T Peltenburg; E M Verdegaal; A Gorter; S A Bres; K L Franken; M Hahne; J P Albar; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

8.  Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL.

Authors:  S Gudowius; K Recker; H-J Laws; U Dirksen; A Tröger; U Wieczorek; S Furlan; U Göbel; H Hanenberg
Journal:  Klin Padiatr       Date:  2006 Nov-Dec       Impact factor: 1.349

9.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

Authors:  C Imai; K Mihara; M Andreansky; I C Nicholson; C-H Pui; T L Geiger; D Campana
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

10.  Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication.

Authors:  Esther N M Nolte-'t Hoen; Catarina R Almeida; Nadia R Cohen; Shlomo Nedvetzki; Helen Yarwood; Daniel M Davis
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113
View more
  3 in total

Review 1.  The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases.

Authors:  Changjin Yuan; Guanhua Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2012-05

2.  Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.

Authors:  Wing Leung; Ching-Hon Pui; Elaine Coustan-Smith; Jie Yang; Deqing Pei; Kwan Gan; Ashok Srinivasan; Christine Hartford; Brandon M Triplett; Mari Dallas; Asha Pillai; David Shook; Jeffrey E Rubnitz; John T Sandlund; Sima Jeha; Hiroto Inaba; Raul C Ribeiro; Rupert Handgretinger; Joseph H Laver; Dario Campana
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 3.  Cellular immunotherapy in multiple myeloma.

Authors:  Manh-Cuong Vo; Thangaraj Jaya Lakshmi; Sung-Hoon Jung; Duck Cho; Hye-Seong Park; Tan-Huy Chu; Hyun-Ju Lee; Hyeoung-Joon Kim; Sang-Ki Kim; Je-Jung Lee
Journal:  Korean J Intern Med       Date:  2019-02-15       Impact factor: 2.884
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.